Best Practice & Research Clinical Endocrinology & Metabolism
Volume 24, Issue 2 , Pages 219-242 , April 2010

46,XX DSD: the masculinised female

  • Richard J. Auchus, M.D.,Ph.D. (Professor)

      Affiliations

    • Division of Endocrinology and Metabolism, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8857, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 214 648 6751; Fax: 1 +214 648 8917.
    • ,
  • Alice Y. Chang, M.D.,M.S.C.S. (Assistant Professor)

      Affiliations

    • Division of Endocrinology and Metabolism, Department of Internal Medicine, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8857, United States
    • Department of Clinical Sciences, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8857, United States

References 

  1. Griffin JE. Androgen resistance–the clinical and molecular spectrum. The New England Journal of Medicine. 1992;326:611–618
  2. Cutler GB, Glenn M, Bush M, et al. Adrenarche: a survey of rodents, domestic animals and primates. Endocrinology. 1978;103:2112–2118
  3. Orentreich N, Brind JL, Rizer RL, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. The Journal of Clinical Endocrinology and Metabolism. 1984;59:551–555
  4. Auchus RJ, Rainey WE. Adrenarche - physiology, biochemistry and human disease. Clinical Endocrinology. 2004;60:288–296
  5. Remer T, Boye KR, Hartmann MF, et al. Urinary markers of adrenarche: reference values in healthy subjects, aged 3–18 years. The Journal of Clinical Endocrinology and Metabolism. 2005;90:2015–2021
  6. Gell JS, Carr BR, Sasano H, et al. Adrenarche results from development of a 3β-hydroxysteroid dehydrogenase-deficient adrenal reticularis. The Journal of Clinical Endocrinology and Metabolism. 1998;83:3695–3701
  7. Nguyen AD, Mapes SM, Corbin CJ, et al. Morphological adrenarche in rhesus macaques: development of the zona reticularis is concurrent with fetal zone regression in the early neonatal period. The Journal of Endocrinology. 2008;199:367–378
  8. Auchus RJ, Lee TC, Miller WL. Cytochrome b5 augments the 17,20 lyase activity of human P450c17 without direct electron transfer. The Journal of Biological Chemistry. 1998;273:3158–3165
  9. Ghayee HK, Auchus RJ. Basic concepts and recent developments in human steroid hormone biosynthesis. Reviews in Endocrine & Metabolic Disorders. 2007;8:289–300
  10. Suzuki T, Sasano H, Takeyama J, et al. Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. Clinical Endocrinology. 2000;53:739–747
  11. Geissler WM, Davis DL, Wu L, et al. Male pseudohermaphroiditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. Nature Genetics. 1994;7:34–39
  12. Nakamura Y, Hornsby PJ, Casson P, et al. Type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) contributes to testosterone production in the adrenal reticularis. The Journal of Clinical Endocrinology and Metabolism. 2009;94:2192–2198
  13. Wilson JD, Auchus RJ, Leihy MW, et al. 5α-androstane-3α,17β-diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane-3α,17α-diol-20-one as a key intermediate. Endocrinology. 2003;144:575–580
  14. Biswas MG, Russell DW. Expression cloning and characterization of oxidative 17β- and 3α-hydroxysteroid dehydrogenases from rat and human prostate. The Journal of Biological Chemistry. 1997;272:15959–15966
  15. Gupta MK, Guryev OL, Auchus RJ. 5α-reduced C21 steroids are substrates for human cytochrome P450c17. Archives of Biochemistry and Biophysics. 2003;418:151–160
  16. Speiser PW, White PC. Congenital adrenal hyperplasia. The New England Journal of Medicine. 2003;349:776–788
  17. Therrell BLJ, Berenbaum SA, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics. 1998;101:583–590
  18. White PC, Grossberger D, Onufer BJ, et al. Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proceedings of the National Academy of Sciences of the United States of America. 1985;82:1089–1093
  19. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocrine Reviews. 2000;21:245–291
  20. Krone N, Braun A, Weinert S, et al. Multiplex minisequencing of the 21-hydroxylase gene as a rapid strategy to confirm congenital adrenal hyperplasia. Clinical Chemistry. 2002;48:818–825
  21. Krone N, Braun A, Roscher AA, et al. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. The Journal of Clinical Endocrinology and Metabolism. 2000;85:1059–1065
  22. Tonetto-Fernandes V, Lemos-Marini SH, Kuperman H, et al. Serum 21-deoxycortisol, 17-hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11β-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2179–2184
  23. Janzen N, Peter M, Sander S, et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. The Journal of Clinical Endocrinology and Metabolism. 2007;92:2581–2589
  24. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. The Journal of Clinical Endocrinology and Metabolism. 2004;89:453–462
  25. Van Wyk JJ, Gunther DF, Ritzén EM, et al. The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 1996;81:3180–3189
  26. Speiser PW, Agdere L, Veshiba H, et al. Aldosterone synthesis in patients with salt-wasting congenital adrenal hyperplasia (21-hydroxylase deficiency) and complete absence of adrenal 21-hydroxylase (P450c21). New England Journal of Medicine. 1991;321:145–149
  27. Laue L, Merke DP, Jones JV, et al. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 1996;81:3535–3539
  28. Lin-Su K, Vogiatzi MG, Marshall I, et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3318–3325
  29. Kim MS, Merke DP. Cardiovascular disease risk in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Seminars in Reproductive Medicine. 2009;27:316–321
  30. Falhammar H, Filipsson H, Holmdahl G, et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2007;92:110–116
  31. Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. The Journal of Clinical Endocrinology and Metabolism. 1994;79:1328–1333
  32. Lo JC, Schwitzgebel VM, Tyrrell JB, et al. Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 1999;84:930–936
  33. Casteràs A, De Silva P, Rumsby G, et al. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clinical Endocrinology. 2009;70:833–837
  34. Stikkelbroeck NM, Beerendonk CC, Willemsen WN, et al. The long term outcome of feminizing genital surgery for congenital adrenal hyperplasia: anatomical, functional and cosmetic outcomes, psychosexual development, and satisfaction in adult female patients. Journal of Pediatric and Adolescent Gynecology. 2003;16:289–296
  35. Lin WC, Chang CY, Shen YY, et al. Use of autologous buccal mucosa for vaginoplasty: a study of eight cases. Human Reprodroduction. 2003;18:604–607
  36. Ravichandran R, Lafferty F, McGinniss MJ, et al. Congenital adrenal hyperplasia presenting as massive adrenal incidentalomas in the sixth decade of life: report of two patients with 21-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 1996;81:1776–1779
  37. Falhammar H, Filipsson H, Holmdahl G, et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2007;92:4643–4649
  38. David M, Forest MG. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. The Journal of Pediatrics. 1984;105:799–803
  39. Nimkarn S, New MI. Prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Molecular and Cellular Endocrinology. 2009;300:192–196
  40. New M, Carlson A, Obeid J, et al. Extensive personal experience: prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. The Journal of Clinical Endocrinology and Metabolism. 2001;5651–5657
  41. Hirvikoski T, Nordenstrom A, Lindholm T, et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. The Journal of Clinical Endocrinology and Metabolism. 2007;92:542–548
  42. Rösler A, Leiberman E, Cohen T. High frequency of congenital adrenal hyperplasia (classic 11-β-hydroxylase deficiency) among Jews from Morocco. American Journal of Medical Genetics. 1992;42:827–834
  43. White PC, Curnow KM, Pascoe L. Disorders of steroid 11β-hydroxylase isozymes. Endocrine Reviews. 1994;15:421–438
  44. Mornet E, Dupont J, Vitek A, et al. Characterization of two genes encoding human steroid 11β-hydroxylase (P45011β). The Journal of Biological Chemistry. 1989;264:20961–20967
  45. Curnow KM, Slutsker L, Vitek J, et al. Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7 and 8. Proceedings of the National Academy of Sciences of the United States of America. 1993;90:4552–4556
  46. Fardella CE, Hum DW, Rodriguez H, et al. Gene conversion in the CYP11B2 gene encoding aldosterone synthase (P450c11AS) is associated with, but does not cause, the syndrome of corticosterone methyl oxidase II deficiency. The Journal of Clinical Endocrinology and Metabolism. 1996;81:321–326
  47. White PC, Dupont J, New MI, et al. A mutation in CYP11B1 (Arg 448→His) associated with steroid 11β-hydroxylase deficiency in Jews of Moroccan origin. The Journal of Clinical Investigation. 1991;87:1664–1667
  48. Lifton R, Dluhy RG, Powers M, et al. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;335:262–265
  49. Portrat S, Mulatero P, Curnow KM, et al. Deletion hybrid genes, due to unequal crossing over between CYP11B1 (11β-hydroxylase) and CYP11B2(aldosterone synthase) cause steroid 11β-hydroxylase deficiency and congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3197–3201
  50. Hampf M, Dao NT, Hoan NT, et al. Unequal crossing-over between aldosterone synthase and 11β-hydroxylase genes causes congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 2001;86:4445–4452
  51. Rösler A, Leiberman E, Sack J, et al. Clinical variability of congenital adrenal hyperplasia due to 11-β-hydroxylase deficiency. Hormones Research. 1982;16:133–141
  52. Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 1983;56:222–229
  53. Zhu YS, Cordero JJ, Can S, et al. Mutations in CYP11B1 gene: phenotype-genotype correlations. American Journal of Medical Genetics A. 2003;122A:193–200
  54. Simm PJ, Zacharin MR. Successful pregnancy in a patient with severe 11-β-hydroxylase deficiency and novel mutations in CYP11B1 gene. Hormone Research. 2007;68:294–297
  55. Rösler A, Leiberman E, Rosenmann A, et al. Prenatal diagnosis of 11β-hydroxylase deficiency congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism. 1979;49:546–551
  56. Cerame BI, Newfield RS, Pascoe L, et al. Prenatal diagnosis and treatment of 11β-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3129–3134
  57. Bongiovanni AM. The adrenogenital syndrome with deficiency of 3β-hydroxysteroid dehydrogenase. The Journal of Clinical Investigation. 1962;41:2086
  58. Simard J, Moisan AM, Morel Y. Congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase/D5–D4 isomerase deficiency. Seminars in Reproductive Medicine. 2002;20:255–276
  59. Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic proof for type II 3β-hydroxysteroid dehydrogenase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2002;87:2611–2622
  60. Luu-The V, Lechance Y, Labrie C, et al. Full length cDNA structure and deduced amino acid sequence of human 3β-hydroxy-5-ene steroid dehydrogenase. Molecular Endocrinology (Baltimore, Md.). 1989;3:1310–1312
  61. Rhéaume E, Lachance Y, Zhao HL, et al. Structure and expression of a new complementary DNA encoding the almost exclusive 3β-hydroxysteroid dehydrogenase/D5-D4-isomerase in human adrenals and gonads. Molecular Endocrinology (Baltimore, Md.). 1991;5:1147–1157
  62. Auchus RJ. The backdoor pathway to dihydrotestosterone. Trends in Endocrinology and Metabolism. 2004;15:432–438
  63. Casey ML, MacDonald PC. Extra-adrenal formation of a mineralocorticoid: deoxycorticosterone and deoxycorticosterone sulfate biosynthesis and metabolism. Endocrine Reviews. 1982;3:396–403
  64. Peterson RE, Imperato-McGinley J, Gautier T, et al. Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. The New England Journal of Medicine. 1985;313:1182–1191
  65. Shackleton C, Malunowicz E. Apparent pregnene hydroxylation deficiency (APHD): seeking the parentage of an orphan metabolome. Steroids. 2003;68:707–717
  66. Miller WL. Regulation of steroidogenesis by electron transfer. Endocrinology. 2005;146:2544–2550
  67. Otto DM, Henderson CJ, Carrie D, et al. Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Molecular and Cellular Biology. 2003;23:6103–6116
  68. Huang N, Pandey AV, Agrawal V, et al. Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. American Journal of Human Genetics. 2005;76:729–749
  69. Shackleton C, Marcos J, Arlt W, et al. Prenatal diagnosis of P450 oxidoreductase deficiency (ORD): a disorder causing low pregnancy estriol, maternal and fetal virilization, and the Antley-Bixler syndrome phenotype. American Journal of Medical Genetics A. 2004;129:105–112
  70. Homma K, Hasegawa T, Nagai T, et al. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2643–2649
  71. Arlt W, Walker EA, Draper N, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet. 2004;363:2128–2135
  72. Flück CE, Tajima T, Pandey AV, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nature Genetics. 2004;36:228–230
  73. Fukami M, Nishimura G, Homma K, et al. Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. The Journal of Clinical Endocrinology and Metabolism. 2009;94:1723–1731
  74. Shackleton C, Marcos J, Malunowicz EM, et al. Biochemical diagnosis of Antley-Bixler syndrome by steroid analysis. American Journal of Medical Genetics A. 2004;128:223–231
  75. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrine Reviews. 1994;15:342–355
  76. Simpson ER, Mahendroo MS, Means GD, et al. Tissue-specific promoters regulate aromatase cytochrome P450 expression. Clinical Chemistry. 1993;39:317
  77. Conte FA, Grumbach MM, Ito Y, et al. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). The Journal of Clinical Endocrinology and Metabolism. 1994;78:1287–1292
  78. Carani C, Qin K, Simoni M, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. The New England Journal of Medicine. 1997;337:91–95
  79. Grumbach MM, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. The Journal of Clinical Endocrinology and Metabolism. 1999;84:4677–4694
  80. Jones ME, Boon WC, McInnes K, et al. Recognizing rare disorders: aromatase deficiency. Nature Clinical Practice. Endocrinology & Metabolism. 2007;3:414–421
  81. Lin L, Ercan O, Raza J, et al. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. The Journal of Clinical Endocrinology and Metabolism. 2007;92:982–990
  82. Sir-Petermann T, Maliqueo M, Angel B, et al. Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Human Reproduction. 2002;17:2573–2579
  83. Manganiello PD, Adams LV, Harris RD, et al. Virilization during pregnancy with spontaneous resolution postpartum: a case report and review of the English literature. Obstetrical & Gynecological Survey. 1995;50:404–410
  84. Spitzer RF, Wherrett D, Chitayat D, et al. Maternal luteoma of pregnancy presenting with virilization of the female infant. Journal of Obstetrics and Gynaecology Canada. 2007;29:835–840
  85. Hensleigh PA, Carter RP, Grotjan HEJ. Fetal Protection against masculinization with hyperreactio luteinalis and virilization. The Journal of Clinical Endocrinology and Metabolism. 1975;40:816–823
  86. Hensleigh PA, Woodruff JD. Differential maternal-fetal response to androgenizing luteoma or hyperreactio luteinalis. Obstetrical & Gynecological Survey. 1978;33:262–271
  87. Noordam C, Dhir V, McNelis JC, et al. Inactivating PAPSS2 mutations in a patient with premature pubarche. The New England Journal of Medicine. 2009;360:2310–2318
  88. Rosa FW. Virilization of the female foetus with maternal danazol exposure. American Journal of Obstetrics & Gynaecology. 1984;149:99–100
  89. Elterman JJ, Hagen GA. Aldosteronism in pregnancy: association with virilization of female offspring. The Southern Medical Journal. 1983;76:514–516
  90. Fuller PJ, Pettigrew IG, Pike JW, et al. An adrenal adenoma causing virilization of mother and infant. Clinical Endocrinology. 1983;18:143–153
  91. Grumbach MM, Ducharme JR, Moloshok RE. On the fetal masculinizing action of certain oral progestins. The Journal of Clinical Endocrinology and Metabolism. 1959;19:1369–1380
  92. Bell RJ. Fetal virilisation due to maternal Krukenberg tumor. Lancet. 1977;1:1162–1163
  93. Verhoeven AT, Mastboom JL, van Leusden HA, et al. Virilization in pregnancy coexisting with an (ovarian) mucinous cystadenoma: a case report and review of virilizing ovarian tumors in pregnancy. Obstetrical & Gynecological Survey. 1973;28:597–622
  94. Kirk JMW, Perry LA, Shand WS, et al. Pseudohermaphroditism due to a maternal adrenocortical tumor. The Journal of Clinical Endocrinology and Metabolism. 1990;70:1280–1284

PII: S1521-690X(09)00142-0

doi: 10.1016/j.beem.2009.11.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 24, Issue 2 , Pages 219-242 , April 2010

Article Tools

* Image Usage & Resolution